Terms: = Uterine cancer AND JAK1, ENSG00000162434, P23458, JTK3, JAK1B, JAK1A, 3716 AND Prognosis
4 results:
1. CD146
Yu Z; Zhang Q; Wei S; Zhang Y; Zhou T; Zhang Q; Shi R; Zinovkin D; Pranjol ZI; Zhang J; Wang H
Cell Commun Signal; 2024 Mar; 22(1):170. PubMed ID: 38459564
[TBL] [Abstract] [Full Text] [Related]
2. Discordant prognosis of mismatch repair deficiency in colorectal and endometrial cancer reflects variation in antitumour immune response and immune escape.
Glaire MA; Ryan NA; Ijsselsteijn ME; Kedzierska K; Obolenski S; Ali R; Crosbie EJ; Bosse T; de Miranda NF; Church DN
J Pathol; 2022 Jul; 257(3):340-351. PubMed ID: 35262923
[TBL] [Abstract] [Full Text] [Related]
3. The anti-neoplastic activities of aloperine in HeLa cervical cancer cells are associated with inhibition of the IL-6-jak1-STAT3 feedback loop.
Chen YD; Cai FY; Mao YZ; Yang YS; Xu K; Liu XF; Fan WW; Chen W; Jiang FQ; Zhang H
Chin J Nat Med; 2021 Nov; 19(11):815-824. PubMed ID: 34844720
[TBL] [Abstract] [Full Text] [Related]
4. Combined inhibition of jak1/2 and DNMT1 by newly identified small-molecule compounds synergistically suppresses the survival and proliferation of cervical cancer cells.
She S; Zhao Y; Kang B; Chen C; Chen X; Zhang X; Chen W; Dan S; Wang H; Wang YJ; Zhao J
Cell Death Dis; 2020 Sep; 11(9):724. PubMed ID: 32895373
[TBL] [Abstract] [Full Text] [Related]
